摘要
Cardiovascular disease （CVD） is a leading life-threatening chronic disease in China. In the primary and secondary prevention, remarkable achievements have been made during past decades. In treating coronary artery disease （CAD）, for example, the advanced treatment approaches, suchas percutaneous coronary intervention （PCI） guided by intracoronary imaging, minimally-invasive coronary artery bypass graft （CABG）, and novel drugs for better control of the risk factors including hypertension, hyperglycemia and dyslipidemia, have been widely used in clinical practice.
Cardiovascular disease （CVD） is a leading life-threatening chronic disease in China. In the primary and secondary prevention, remarkable achievements have been made during past decades. In treating coronary artery disease （CAD）, for example, the advanced treatment approaches, suchas percutaneous coronary intervention （PCI） guided by intracoronary imaging, minimally-invasive coronary artery bypass graft （CABG）, and novel drugs for better control of the risk factors including hypertension, hyperglycemia and dyslipidemia, have been widely used in clinical practice.
